Skip to main content
OpenTrials
Completed

NCT Number: NCT01344941

Human Immune Responses Toward HIV-1 Envelope Antigens

The primary objectives of this study is to

* Define the envelope-specific B-cell and T-cell responses in humans who have received a St. Jude HIV-1 vaccine. * Describe mechanisms of HIV-1 envelope processing and consequent B-cell and T-cell activities.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The goal of this protocol is to understand how human lymphocytes respond to HIV-1 antigens in the context of vaccination or infection. This protocol will support understanding of the immune response by providing a source of lymphocytes and serum from selected individuals to study in laboratory based investigations. Blood samples from individuals who have received an HIV-1 vaccine, individuals who are HIV-1-infected, and individuals who are HIV-1-uninfected are requested to: (1) test previously vaccinated volunteers for HIV-1 envelope-specific B-cell and T-cell immune activities, and (2) increase understanding of how the human immune system processes and responds to HIV-1 envelope proteins.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant is greater than or equal to 18 years of age.
  • Participant is in good general health.
  • Participant weighs ≥ 110 pounds.
  • Participant has hemoglobin > 12 gm/dL within last 12 weeks.

Group 1 (Vaccinees) only Inclusion Criteria:

  • Participant has previously received one of the St. Jude HIV-1 vaccines via enrollment in prior St. Jude HIV vaccine studies.

Group 2 (HIV positive) only Inclusion Criteria:

  • Participant is HIV-1 positive by medical record review.

Group 3 (HIV negative) only Inclusion Criteria:

  • Participant is HIV-1 negative as determined by HIV ELISA.

Exclusion criteria

  • Participant is unable or unwilling to give written informed consent.
  • Participant is pregnant female.

Group 2 (HIV positive) only Exclusion Criteria:

  • Participant is enrolled in other clinical trials that include any blood sampling such that the cumulative blood draws would exceed that established as constituting minimal risk (e.g., more than 550 ml in an 8 week period with collection more frequently than 2 times per week)

Treatment and study plan

Primary outcomes

  1. Specific B cell and T cell responses in humans who received St Jude HIV-1 Vaccine

    Time frame: 5 years

    The outcome measures will be assessed in such a way that individuals will be sampled longitudinally (every 6months) until the immune response is no longer detectable by HIV ELISA or until the 5 year study period is complete, whichever comes first. A volume of 120 ml will be collected at each visit for immune response assays (both B-cell and T-cell) and 2 ml of blood will be collected for the HIV ELISA.

Secondary outcomes

  1. Mechanism of HIV-1 envelope processing B cell and T cell activities

    Time frame: 5 years

    The outcome measures will be assessed by new developments in the field that may ultimately yield improved methods for the testing of antigen processing and B-cell and T-cell functions, in which case new assays will be adopted for use in this study. Lymphocyte samples will also support HLA testing. Samples will be used for continued B-cell and T-cell studies supportive of the 2 study objectives. The volume of blood drawn will be closely monitored and will remain below the defined criteria for minimal risk research.

Sponsors and collaborators

Lead sponsor

St. Jude Children's Research Hospital

Other

Registry information

Acronym: HIVBLD

Important dates

Study start
2010
Primary completion
2015
Study completion
2015
First posted
Apr 29, 2011
Registry last updated
Nov 5, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.